ERAAs for menopause treatment: Welcome the 'designer estrogens'.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28628428.
- Also identified by DOI 10.3949/ccjm.84a.15140.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Estrogen receptor agonist-antagonists (ERAAs) selectively inhibit or stimulate estrogen-like action in targeted tissues. This review summarizes how ERAAs can be used in combination with an estrogen or alone to treat menopausal symptoms (vasomotor symptoms, genitourinary syndrome of menopause), breast cancer or the risk of breast cancer, osteopenia, osteoporosis, and other female midlife concerns.
Medical subject headings
- Bone Diseases, Metabolic
- Breast Neoplasms
- Estrogens
- Hot Flashes
- Menopause
- Selective Estrogen Receptor Modulators